NexGel (NXGL) Earnings Date & Reports

Key Takeaways

• NEXGEL is expected to report its third-quarter 2026 results around mid-November 2026, covering the period ended September 30, 2026.
• Wall Street consensus points to revenue of roughly $4.19 million, up about 43% from $2.93 million a year earlier, alongside a continued net loss per share.
• The report is the first full quarter to reflect the company's April 2026 acquisition of Celularity's regenerative biomaterials portfolio, now operating as the BioNX Surgical division.
• In the prior quarter, revenue rose 27.8% year over year to $3.69 million but missed the $4.32 million consensus, while the net loss widened on one-time transaction and integration costs.
• Management's going-concern warning and a thin unrestricted cash position keep liquidity and the path to profitability at the center of investor attention.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for NXGL.
• You can also explore Trending AI Robots to see how automated strategies are navigating current market conditions.

Earnings Context and Why It Matters

NEXGEL develops high-water-content hydrogels used in wound care, medical diagnostics, and consumer cosmetics. This report carries extra weight because it is the first full quarter to reflect the company's acquisition of Celularity's regenerative biomaterials portfolio, now consolidated under the BioNX Surgical division. Investors are watching closely whether new biomaterials revenue can offset softness in consumer-branded products and contract manufacturing while narrowing losses. With the stock having fallen sharply over the past year and management having raised substantial doubt about the company's ability to continue as a going concern, this release is a critical checkpoint for assessing liquidity, integration progress, and any credible path toward sustainable profitability.

Earnings Expectations

Consensus estimates call for third-quarter 2026 revenue of approximately $4.19 million, which would represent year-over-year growth of roughly 43% from the $2.93 million reported in the year-ago quarter. Analysts also expect another net loss per share, reflecting ongoing investment in the BioNX Surgical integration. It is worth noting that analyst coverage remains thin, with a single estimate in the consensus, so these figures should be read with caution.

Recent results set a demanding comparison. In the second quarter of 2026, NEXGEL reported revenue of $3.69 million, up 27.8% year over year but below the $4.32 million consensus. The net loss widened to about $3.6 million as the company absorbed intangible-asset amortization, one-time transaction expenses, and costs tied to a strategic recall of its SilverSeal product. The company has beaten consensus estimates on earnings per share in only a handful of its recent quarters, meaning execution and cost control will be closely scrutinized heading into this report.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking small-cap growth stories like NXGL, it offers a structured way to surface comparable names and emerging setups. Consider exploring the AI Screener to put this earnings event into broader market context.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautious. NEXGEL's shares have been highly volatile over the past year, trading well below their late-2024 highs as recurring losses, dilution concerns, and the going-concern disclosure weighed on investor confidence. The company has also experienced significant share-count changes, which have contributed to an elevated loss per share on a reported basis and made quarter-to-quarter comparisons harder to interpret.

Following the last earnings release, the stock exhibited a notable post-announcement drift lower, suggesting the market is quick to punish execution shortfalls. Key risk factors ahead of this print include the pace of BioNX revenue ramp, supply-chain constraints in the newly formed surgical division, and any additional capital raises that could dilute existing shareholders. A narrower-than-expected loss or clear evidence of accelerating biomaterials demand would likely be viewed positively, while another revenue miss or fresh liquidity concerns could reignite selling pressure.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, the central question is whether the BioNX Surgical division can translate its regenerative biomaterials portfolio into sustainable, higher-margin revenue. Management has pointed to the hospital channel as a meaningful growth opportunity, and the strategic SilverSeal recall was undertaken partly to support that channel's launch. Investors should watch for updates on hospital adoption, gross margin trends, and whether supply-chain constraints ease.

Liquidity remains a defining risk. The company ended its second quarter with limited unrestricted cash and negative working capital, and it has signaled it may need additional debt or equity financing. Any new capital raise, and its terms, will matter as much as the operating results themselves.

Finally, watch for progress on the broader product pipeline, including the partnership with STADA and expansion of consumer-branded offerings. Evidence of cost discipline and a narrowing loss per share toward break-even would be the clearest signals that NEXGEL is converting acquisition-driven top-line growth into a more durable financial footing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations